Prospective Validation of CD-62L (L-Selectin) as Marker of Durable Response to Infliximab Treatment in Patients With Inflammatory Bowel Disease: A 5-Year Clinical Follow-up

INTRODUCTION: The development of biomarkers to guide management of anti–tumor necrosis factor (TNF) agents in patients with inflammatory bowel disease (IBD) is an unmet need. We developed an in vitro blood assay to predict patient long-term outcome with the anti-TNFα agent infliximab (IFX). METHODS:...

Descripción completa

Detalles Bibliográficos
Autores principales: Bravo, Francisco, Macpherson, Jamie A., Slack, Emma, Patuto, Nicolas, Cahenzli, Julia, McCoy, Kathy D., Macpherson, Andrew J., Juillerat, Pascal
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7886452/
https://www.ncbi.nlm.nih.gov/pubmed/33735154
http://dx.doi.org/10.14309/ctg.0000000000000298

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7886452/
https://www.ncbi.nlm.nih.gov/pubmed/33735154
http://dx.doi.org/10.14309/ctg.0000000000000298

Ejemplares similares